{"id":"https://openalex.org/W4281672607","doi":"https://doi.org/10.2337/db22-1159-p","title":"1159-P: Associations of HOMA2 with Clinical Outcomes in Type 2 Diabetes","display_name":"1159-P: Associations of HOMA2 with Clinical Outcomes in Type 2 Diabetes","publication_year":2022,"publication_date":"2022-05-31","ids":{"openalex":"https://openalex.org/W4281672607","doi":"https://doi.org/10.2337/db22-1159-p"},"language":"en","primary_location":{"id":"doi:10.2337/db22-1159-p","doi":"https://doi.org/10.2337/db22-1159-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db22-1159-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007921065","display_name":"Baoqi Fan","orcid":"https://orcid.org/0000-0001-6728-419X","observed_orcids":["https://orcid.org/0000-0001-6728-419X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"BAOQI FAN","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065637498","display_name":"ERIC S.H. LAU","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ERIC S.H. LAU","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027659686","display_name":"HONGJIANG WU","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"HONGJIANG WU","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012210861","display_name":"MAI SHI","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MAI SHI","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057178566","display_name":"Aimin Yang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"AIMIN YANG","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056539592","display_name":"CADMON K. LIM","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"CADMON K. LIM","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090140597","display_name":"ALICE P. KONG","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ALICE P. KONG","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072979521","display_name":"Elaine Chow","orcid":"https://orcid.org/0000-0002-4147-3387","observed_orcids":["https://orcid.org/0000-0002-4147-3387"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ELAINE CHOW","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045501407","display_name":"RONALD C. MA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"RONALD C. MA","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039556979","display_name":"ANDREA LUK","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ANDREA LUK","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091832416","display_name":"Juliana C.N. Chan","orcid":"https://orcid.org/0000-0003-1325-1194","observed_orcids":["https://orcid.org/0000-0003-1325-1194"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JULIANA C. CHAN","raw_affiliation_strings":["Hong Kong, China, Shatin, Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hong Kong, China, Shatin, Hong Kong","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0775061,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5565999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5565999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.17149999737739563,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.15860000252723694,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9940000176429749},{"id":"https://openalex.org/keywords/homa2","display_name":"HOMA2","score":0.8889999985694885},{"id":"https://openalex.org/keywords/insulin-deficiency","display_name":"insulin deficiency","score":0.8550000190734863},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.9990000128746033},{"id":"https://openalex.org/keywords/insulin-requirement","display_name":"insulin requirement","score":0.5669999718666077},{"id":"https://openalex.org/keywords/c-peptide","display_name":"C-peptide","score":0.7480000257492065},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":0.734000027179718},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.9679999947547913},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.8629999756813049},{"id":"https://openalex.org/keywords/severe-hypoglycemia","display_name":"severe hypoglycemia","score":0.9670000076293945},{"id":"https://openalex.org/keywords/cardiovascular-renal-disease","display_name":"cardiovascular-renal disease","score":0.8799999952316284},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7070000171661377},{"id":"https://openalex.org/keywords/hong-kong-chinese","display_name":"Hong Kong Chinese","score":0.6370000243186951}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8749071359634399},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7160710692405701},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6293193101882935},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.6086744666099548},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5744957327842712},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5484538674354553},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.5039164423942566},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.48970821499824524},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.46462923288345337},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.4305153489112854},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.36447733640670776},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3280089497566223},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.07300335168838501}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db22-1159-p","doi":"https://doi.org/10.2337/db22-1159-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db22-1159-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8700000047683716,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3173984663","https://openalex.org/W4213173497","https://openalex.org/W2411754124","https://openalex.org/W2959825751","https://openalex.org/W7053816486","https://openalex.org/W2751237697","https://openalex.org/W2948552724","https://openalex.org/W2101725562","https://openalex.org/W6958159663","https://openalex.org/W1802478800"],"abstract_inverted_index":{"Background:":[0],"In":[1,30,260],"patients":[2,32,129,262],"with":[3,33,130,213,237,263,273,281],"type":[4],"2":[5],"diabetes":[6],"(T2D)":[7],"negative":[8],"for":[9,247,253,308],"glutamic":[10],"acid":[11],"decarboxylase":[12],"antibodies":[13],"(GADA-)":[14],",":[15,69,177],"the":[16,38,63,87,118,134,186,209,214,217,221,245,274,282],"prognostic":[17],"significance":[18],"of":[19,91,136,144,195,224,276,285,294],"insulin":[20,24,84,89,159,197,226,286],"deficiency":[21],"(ID)":[22],"and":[23,52,76,96,108,122,142,182,205,234,256,266,278,288,296,347,389,436,439],"resistance":[25],"(IR)":[26],"remained":[27],"uncertain.":[28],"Methods:":[29],"4590":[31],"T2D":[34],"consecutively":[35],"enrolled":[36],"to":[37,100,116,157,170,172,242,270,303],"Hong":[39],"Kong":[40],"Diabetes":[41,320,336],"Register":[42],"in":[43,57],"1995-2012":[44],"followed":[45],"up":[46],"till":[47],"2019,":[48],"we":[49,70],"measured":[50],"GADA":[51],"fasting":[53],"C":[54],"peptide":[55],"(CP)":[56],"stored":[58],"samples":[59],"at":[60,92],"baseline.":[61],"Using":[62],"updated":[64],"homeostasis":[65],"model":[66,115],"assessment":[67,293],"(HOMA2)":[68],"defined":[71,82],"below-median":[72],"HOMA2-%B":[73,137],"as":[74,79,86],"ID":[75,152,265,277,295],"above-median":[77],"HOMA2-IR":[78,145],"IR.":[80],"We":[81,111],"incident":[83,196,225],"use":[85,227],"first":[88],"prescription":[90],"least":[93],"28":[94],"days":[95],"used":[97,112],"ICD-9":[98],"codes":[99],"define":[101],"cardiovascular-renal":[102,235],"diseases,":[103],"severe":[104],"hypoglycemia":[105],"event":[106],"(SHE)":[107],"all-cause":[109,183,206],"mortality.":[110],"Cox":[113],"regression":[114],"examine":[117],"associations":[119,246],"between":[120],"HOMA2":[121,132,299],"clinical":[123,271,290],"outcomes.":[124,291],"Results:":[125],"Amongst":[126],"3198":[127],"GADA-":[128,261],"available":[131],"data,":[133],"median":[135],"was":[138,146,154],"52.4":[139],"(33.1,":[140],"60.9)":[141],"that":[143],"1.6":[147],"(1.1,":[148],"1.8)":[149],".":[150],"The":[151,189,292,432],"group":[153,191,219],"more":[155],"likely":[156,169],"initiate":[158],"treatment":[160],"[adjusted":[161],"HR":[162],"(95%CI)":[163],"1.26":[164],"(1.11-1.42)":[165],"]":[166],"but":[167],"less":[168],"progress":[171],"chronic":[173],"kidney":[174,179],"disease":[175,180],"(CKD)":[176],"end-stage":[178],"(ESKD)":[181],"mortality":[184,207],"than":[185,208],"non-ID":[187],"group.":[188,211],"IR":[190,267,279,297],"had":[192,220],"increased":[193],"risks":[194],"therapy":[198],"[HR":[199,228],"1.13":[200],"(1.00-1.27)":[201],"],":[202,232],"CKD,":[203],"ESKD,":[204],"non-IR":[210],"Compared":[212],"ID-/IR-":[215],"group,":[216],"ID/IR":[218],"highest":[222,283],"hazard":[223],"1.59":[229],"(1.30,":[230],"1.94)":[231],"SHE":[233],"diseases":[236],"HRs":[238],"ranging":[239],"from":[240],"1.45":[241],"2.09,":[243],"although":[244],"complications":[248],"became":[249],"insignificant":[250],"after":[251],"adjusting":[252],"metabolic":[254],"factors":[255],"baseline":[257],"treatments.":[258],"Conclusions:":[259],"T2D,":[264],"contributed":[268],"differently":[269],"outcomes":[272],"co-existence":[275],"associated":[280],"risk":[284,301,306],"requirement":[287],"adverse":[289],"using":[298],"improved":[300],"stratification":[302],"identify":[304],"high":[305],"people":[307],"individualized":[309],"intervention.":[310],"Disclosure":[311],"B.Fan:":[312],"None.":[313,315,357,359,361,363,365],"A.Luk:":[314],"J.C.Chan:":[316],"Board":[317],"Member;":[318],"Asia":[319],"Foundation,":[321],"Consultant;":[322],"Bayer":[323,413,422],"AG,":[324,408,414,423],"Boehringer":[325,381,415],"Ingelheim":[326,416],"International":[327,417],"GmbH,":[328,418],"Celltrion,":[329],"Merck":[330],"Sharp":[331],"&":[332],"Dohme":[333],"Corp.,":[334],"Roche":[335],"Care,":[337],"Viatris":[338],"Inc.,":[339,404,428],"Research":[340,379,397,419,437,441],"Support;":[341,380,398,420],"Applied":[342],"Therapeutics,":[343],"AstraZeneca,":[344,376,385,421],"Eli":[345,387],"Lilly":[346,388],"Company,":[348,390],"Hua":[349,399],"Medicine,":[350,400],"Servier":[351],"Laboratories,":[352],"Stock/Shareholder;":[353,392],"GemVCare":[354],"Ltd.":[355],"E.S.H.Lau:":[356],"H.Wu:":[358],"M.Shi:":[360],"A.Yang:":[362],"C.K.Lim:":[364],"A.P.Kong:":[366],"Advisory":[367],"Panel;":[368],"Abbott,":[369],"Kyowa":[370],"Kirin":[371],"Co.,":[372],"Ltd.,":[373],"Other":[374,411],"Relationship;":[375,412],"Novo":[377,424],"Nordisk,":[378],"Ingelheim,":[382],"Speaker's":[383,405],"Bureau;":[384,406],"Bayer,":[386],"Sanofi,":[391],"Aptorum":[393],"Group":[394],"Limited.":[395],"E.Chow:":[396],"Medtronic,":[401],"Powder":[402],"Pharmaceuticals":[403],"Novartis":[407],"Sanofi.":[409],"R.C.Ma:":[410],"Nordisk":[425],"A/S,":[426],"Pfizer":[427],"Tricida,":[429],"Inc.":[430],"Funding":[431],"HKG":[433],"Health":[434],"Medical":[435],"Fund":[438,443],"RGC":[440],"Impact":[442]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2022-06-13T00:00:00"}